

- — <sup>12</sup>CQ TECHNOLOGY
- — BIOCHIP TECHNOLOGY

# ARCHER



## Archer Materials

AGM Presentation | November 2024

# Corporate Overview

## Directors



**Greg English**  
(Executive Chair)  
LLB, BE (Mining)



**Ken Williams**  
(Non- Executive Director)  
B.Econ (HONS), MAppFin,  
FAICD



**Bernadette Harkin**  
(Non- Executive Director)  
MBA, GAICD

## Management



**Damien Connor**  
(Chief Financial Officer /  
Company Secretary)  
CA GAICD AGIA B.Com



**Dr Simon Ruffell**  
(Chief Technology Officer)  
PhD, MEng

ASX Code: **AXE**

## CORPORATE SNAPSHOT

Shares on Issue

**255m**

Share Price

**\$0.39**

12 November 2024

Market  
Capitalisation

**\$99m**

Cash


**\$16m**

30 September 2024

Debt

**Nil**


Shareholders



TOP 20

Archer Materials is building on its foundation of carbon-based technologies to develop products that will help solve critical problems.

## Quantum Technology




A carbon-based quantum device for applications like sensing and computing and the possibility of integrating with other electronics.

## Biochip



Highly sensitive, chip-based graphene sensors for at-home management and treatment of chronic diseases.


## TMR Sensor



TMR sensors are more sensitive, have higher bandwidth and lower power consumption.


## Technology development strategy focussed on megatrends.

### Quantum Technologies



- Quantum computing offers unprecedented processing power for solving complex problems
- Advanced quantum sensors allow for highly precise measurements
- Quantum computing accelerates AI algorithms, enhancing machine learning, pattern recognition, and data processing

ARCHER TECHNOLOGIES  
**<sup>12</sup>CQ Project**



### Ageing Population



- Increased focus on “at home” care.
- Development of easy-to-use home diagnostic tools that allow elderly users to monitor chronic conditions like diabetes, cardiovascular health, and kidney function.
- Focus on cost-effective solutions that make home testing affordable, potentially reducing the burden on the public healthcare system

ARCHER TECHNOLOGIES  
**Biochip**




### Digitalisation



- Increasing use of data analytics and big data technologies – exponential growth in data centres
- New technologies required to make data centres more efficient and cost-effective
- Technological advancement driving exponential growth in the digital economy

ARCHER TECHNOLOGIES  
**TMR sensor**



### Decarbonisation




- Structural trend driving exponential growth of renewable energy sources
- Existing transmission network unable to cope with influx of renewable energy
- AI and technology solutions are required to make the network stable

Archer is assessing  
new technologies  
for development



# Biochip – the problem & addressable market

Archer is developing a biochip that uses the highly sensitive, high speed, low power sensors to detect ions that could be integrated into a lab-on-a-chip device for advanced medical diagnostics.



Chronic kidney disease affects more than 850 million people (>10% of the population).<sup>1</sup>

Abnormal potassium levels can be lethal → kidney disease patients are at high risk as the kidneys control electrolytes like potassium.

Testing can only be done in a clinical setting with analysis done via a lab. Current testing is performed monthly, which is too slow and not done frequently enough.

>US\$3B total addressable of the >US\$80B renal disease market.<sup>2</sup>

Extendable to heart disease and treatment.

Extendable to other ion sensing applications in medicine and agriculture.

1. Kidney Care UK "1 in 10 people...", Hill N. et al. PLOS ONE (2016)  
2. Yole "Biosensors Marketing Report 2024-32", Market Research Future "Renal Disease Market Report". Bottom-up estimate using refs above

# Biochip – a ‘lab-on-a-chip’ for at home testing

Developing a biosensor, based in graphene field effect transistors (gFET) to test for potassium in chronic kidney disease.

High accuracy to bring testing for diseases like chronic kidney disease into the home at a low cost.



Game changing at-home potassium testing



High frequency of testing enables physicians to more effectively monitor and manage patients with the best available therapies and treatment.



Improved treatment for dialysis patients.



Potassium lowering drugs produced by pharmaceutical companies could be safely and regularly prescribed.



Patients in remote areas are empowered to take-action before its too late.

MUTUAL BENEFIT FOR ARCHER AND DRUG COMPANIES

# Biochip – Potassium Sensing - Status

Proof of concept


Feasibility

Development & Optimisation

----- Launch

**BEGINNING THESE PHASES**

- Initial data
- Foundry supplier sourced
- Academic support




- Work ramping up in Sydney-Archer
- Forming partnerships with global diagnostics companies
- Building access to clinical advisors, potential trial locations
- Building academic partnerships in Australia




# Quantum technology

## Carbon Materials

Nano-onions



Patternable films



Cross-section (electron microscopy)




## Applications



Magnetometers



MHz to THz detectors



Magnetic microscopes



Qubits



# Quantum computing enables hundreds of use cases each with significant value-creation potential.




4 types

of computational problems and how quantum computing addresses them.

100+

USE CASES

Machine learning applications will impact most, if not all, industries.



### SIMULATION

Precisely and efficiently simulate the dynamics of a quantum system.

- **Pharma:** drug discovery  
\$40 billion to \$80 billion
- **Aerospace:** computational fluid dynamics  
\$10 billion to \$20 billion
- **Chemistry:** catalyst design  
\$20 billion to \$50 billion
- **Energy:** solar conversion  
\$10 billion to \$30 billion
- **Finance:** market simulation (used in derivatives pricing)  
\$20 billion to \$35 billion



### OPTIMISATION

Efficiently optimise solutions from complex and large data.

- **Logistics:** network optimization  
\$50 billion to \$100 billion
- **Insurance:** risk management  
\$10 billion to \$20 billion
- **Finance:** portfolio optimization  
\$20 billion to \$50 billion
- **Aerospace:** route optimization  
\$20 billion to \$50 billion



### MACHINE LEARNING

Process data sets to reduce noise and simplify computations faster.

- **Automotive:** autonomous vehicle AI algorithm design  
Up to \$10 billion
- **Finance:** money laundering and fraud prevention  
\$20 billion to \$30 billion
- **Tech:** generative, foundation and horizontal AI  
\$50 billion to \$100 billion




### CRYPTOGRAPHY


Improve encryption protecting critical information.

- **Government:** encryption and decryption (related to secure communications and cybersecurity)
- **Corporate:** encryption (related to secure communications and cybersecurity)  
Up to \$10 billion

Archer considers quantum technology to be the next great technological advance. Expected large scale adoption after 2030.



Adoption of quantum tech expected to increase with quantum hardware maturity






Quantum computing is expected to rapidly increase in share of total quantum value



Sources:  
BCG analysis  
Krelina, "Quantum technology for military applications" EPJ Quantum Technology (2021); IBM quantum roadmap; IonQ quantum roadmap

# Quantum technology – Status

- Recently bolstered manufacturability and scalability with a new carbon film.
- Probing microscale volumes of carbon material using pESR chip.
- Working with external collaborators to make progress on three fronts:
  - Improving materials properties and scaling to wafer-scale synthesis and processing;
  - Developing microwave resonant circuits to both probe and later control electron spin; and
  - Begun work on electrically detected spin resonance for readout.
- Building on team’s expertise to investigate TMR sensors



# Archer set to tap into high growth TMR sensor market

- Overseas foundry to develop a tunnel magnetoresistance (“TMR”) sensor for Archer for commercial use in industrial applications.
- TMR sensors are ideal for many applications, including artificial intelligence, data centres, automotive, and the Internet of Things (IoT).
- TMR leverages quantum phenomena to provide a performance edge over classical incumbents.
- Part of Archer’s <sup>12</sup>CQ project, and leveraging its expertise in quantum mechanics to design advanced TMR sensors.
- Archer will finalise its TMR sensor design in the coming weeks, with the first prototypes to be delivered before the end of the year.
- Early next calendar year, Archer will commence work to optimise the TMR sensor design and engage with potential customers, potentially bringing forward revenue opportunities while it continues <sup>12</sup>CQ quantum development.



## TMR Sensors – Key benefits

- High Sensitivity and Accuracy
- Ideal for detecting very small magnetic fields.
- Bidirectional sensing capabilities
- Low Power Consumption
- Enables use in battery-powered devices.
- Versatility
- Suited for various industries, including (but not limited to) automotive, medical devices, and IoT.



# Two-Year Milestones

## Year 1

Complete R&D phase and prototyping with MultiDimension Technology.

Secure partnerships with manufacturers in key industries.

## Year 2

Begin commercialisation and sales.

Launch pilot projects in key verticals with initial customers.

Archer has the foundations in place to advance its technology towards commercialisation in global markets.

### **Future technologies**

Archer's devices look to solve high value problems.

### **Strong partnerships**

Archer has partnerships with foundries to help manufacture its technologies and with leading research institutions to help develop its technologies.

### **Growing markets**

Archer's technologies have a range of applications across growing markets such as medical diagnostics, data centres, IoT, and automotive.

### **IP portfolio**

A growing IP portfolio of granted and pending patents across key markets such as North America, APAC, and Europe.

## / Summary of Proxies Received

	Votes For	Votes Against	Discretion of Proxy	Abstentions	Excluded
<b>ORDINARY RESOLUTIONS</b>					
<b>RESOLUTION 1 - Adoption of Remuneration Report</b> <i>'That the Remuneration Report for the year ended 30 June 2024 be adopted'</i>	18,169,584 80.99%	3,617,597 16.13%	646,777 2.88%	226,953	12,453,683
<b>RESOLUTION 2 - Re-election of Kenneth Williams as a Director</b> <i>'That Kenneth Williams be re-elected as a Non-Executive Director of the Company.'</i>	31,271,388 89.19%	3,125,137 8.85%	664,777 1.89%	53,392	-
<b>RESOLUTION 3 - Approval to issue Incentive Options to Director Gregory English</b> <i>'To approve the grant a total of 5,000,000 Incentive Options to Gregory English, a Director of the Company, or his nominee, as described in the Explanatory Memorandum.'</i>	17,030,196 76.23%	4,643,171 20.78%	669,002 2.99%	318,542	12,453,683
<b>RESOLUTION 4 - Approval to issue Incentive Options to Director Bernadette Harkin</b> <i>'To approve the grant a total of 3,000,000 Incentive Options to Bernadette Harkin, a Director of the Company, or her nominee, as described in the Explanatory Memorandum.'</i>	17,435,896 78.04%	4,237,471 18.97%	669,002 2.97%	318,542	12,453,683
<b>RESOLUTION 5 - Approval to issue Incentive Options to Director Kenneth Williams</b> <i>'To approve the grant a total of 3,000,000 Incentive Options to Kenneth Williams, a Director of the Company, or his nominee, as described in the Explanatory Memorandum.'</i>	17,425,196 78.00%	4,248,171 19.01%	669,002 2.99%	318,542	12,453,683
<b>SPECIAL RESOLUTION</b>					
<b>RESOLUTION 6 - Approval of 10% additional placement capacity</b> <i>'That, for the purpose of Listing Rule 7.1A, approval is given for the Company to issue Equity Securities totalling up to 10% of the issued capital of the Company (at the time of the issue) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions described in the Explanatory Memorandum.'</i>	32,526,002 93.27%	1,676,218 4.81%	669,003 1.92%	243,371	-

○ — <sup>12</sup>CQ TECHNOLOGY  
○ — BIOCHIP TECHNOLOGY

# ARCHER

## Thank you

### ASX Code: AXE

The Board of Archer authorised this announcement to be given to ASX.

Archer Materials Limited  
(ABN 64 123 993 233)

E: [hello@archerx.com.au](mailto:hello@archerx.com.au)

Visit us at: [archerx.com.au](http://archerx.com.au)

### Sydney

Level 2, 477 Pitt St  
Sydney NSW 2000  
Australia

### Adelaide

Lot Fourteen, Frome Road  
Adelaide SA 5000  
Australia

### Stay in touch

Shareholders are encouraged to take advantage of the benefits of electronic communications by electing to receive communication from the Company and its share registry electronically.

Shareholders can change their communication preferences through the registry website:  
[www.investorcentre.com](http://www.investorcentre.com)

For more information about Archer's activities, and sign up to receive the latest news, reports, presentations and ASX released, please visit the following:

### LinkedIn

[www.linkedin.com/company/archerxau](http://www.linkedin.com/company/archerxau)

### Sign up to our Newsletter

<http://eepurl.com/dKosXI>

# Disclaimer

The material contained in this document is a presentation of general information about the activities of Archer Materials Ltd and its related bodies corporate (together the "Archer Group"), current as at the date of this presentation. It is provided in summary and does not purport to be complete. You should not rely upon it as advice for investment purposes, as it does not take into account your investment objectives, financial position or needs. These factors should be considered, with or without professional advice, when deciding if an investment is appropriate. To the extent permitted by law, no responsibility for any loss arising in any way (including by way of negligence) from anyone acting or refraining from acting as a result of this material is accepted by the Archer Group, including any of its related bodies corporate.

This document may contain forward-looking statements with respect to the financial condition, results of operations, and business strategy of the Archer Group. These forward-looking statements are based on estimates, projections and assumptions made by the Archer Group about circumstances and events that have not yet taken place. Although the Archer Group believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Archer Group's control, and which may cause actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements (and from past results). The Archer Group makes no representation or warranty as to the accuracy of any forward-looking statements in this presentation and undue reliance should not be placed upon such statements. Forward-looking statements may be identified by words such as "aim", "anticipate", "assume", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "should", "will", or "would" or the negative of such terms or other similar expressions that are predictions of or otherwise indicate future events or trends. The forward-looking statements included in this presentation speak only as of the date of this presentation. The Archer Group does not intend to update the forward-looking statements in this presentation in the future.

This presentation contains information which was reported in ASX announcements lodged between 1 October 2017 and 13 February 2024 (together the "Announcements"). All material assumptions and technical parameters set out in the Announcements continue to apply and have not materially changed. The Announcements can be viewed online at <https://www.archerx.com.au>.

Certain statistical and other information included in this presentation is sourced from publicly available third party sources and has not been independently verified.

